MorphoSys Inks Licensing Agreement With Novartis For Preclinical Cancer Programs

 

• MorphoSys AG's 
  MOR+0.86%+ Free Alerts
   subsidiary Constellation Pharmaceuticals Inc has entered into a global licensing agreement with Novartis AG 
  NVS+0.67%+ Free Alerts
   to research, develop and commercialize its pre-clinical inhibitors of a novel cancer target. 
• This program was added to MorphoSys' research portfolio following its acquisition of Constellation Pharmaceuticals in 2021 for $1.7 billion.
• "At MorphoSys, we will continue to focus our resources on driving our late- and mid-stage oncology pipeline forward, which has the potential to enhance the standard and quality of care in difficult-to-treat and debilitating types of blood cancers," said Jean-Paul Kress, CEO of MorphoSys. 
• Novartis will assume full responsibility for the program's subsequent research, development, and commercialization activities. 
• As part of the agreement, MorphoSys receives an immediate upfront payment of $23 million. 
• MorphoSys will be eligible to receive milestone payments from Novartis in addition to mid-single- to low-double-digit royalties on program net sales.

https://www.benzinga.com/general/biotech/22/12/29990139/morphosys-inks-licensing-agreement-with-novartis-for-preclinical-cancer-programs